Profile of eliglustat tartrate in the management ofgaucher disease

Therapeutics and Clinical Risk Management

Volumn 12, Issue , 2016, Pages 53-58

  Sechi, Annalisa ^a   Dardis, Andrea ^a   Bembi, Bruno ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Eliglustat tartrate; Enzyme replacement therapy; Gaucher disease; Substrate reduction therapy

Indexed keywords

ALGLUCERASE; CERAMIDE GLUCOSYLTRANSFERASE; ELIGLUSTAT; IMIGLUCERASE; MIGLUSTAT; PLACEBO; TALIGLUCERASE ALFA; VELAGLUCERASE ALFA;

ADVERSE OUTCOME; ARTHRALGIA; BIOLOGICAL THERAPY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; ENZYME REPLACEMENT; FATIGUE; GAUCHER DISEASE; HEADACHE; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVIEW; SUBSTRATE REDUCTION THERAPY;

EID: 84955324890     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S73226     Document Type: Review

References (41)

1. Beutler E, Grabowski GA. Glucosylceramid lipidoses: Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 1995:2641-2670.
2. Mehta A. Epidemiology and natural history of Gaucher’s disease. Eur J Intern Med. 2006;17:S2-S5.
3. Patterson MC, Horowitz M, Abel RB, et al. Isolated horizontal supra- nuclear gaze palsy as a marker of severe systemic involvement in Gaucher’s disease. Neurology. 1993;43:1993-1997.
4. Goker-Alpan O, Schiffmann R, Park JK, et al. Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr. 2003;143:273-276.
5. Elstein D, Alcalay R, Zimran A. The emergence of Parkinson disease among patients with Gaucher disease. Best Pract Res Clin Endocrinol Metab. 2015;29(2):249-259.
6. Chérin P, Rose C, de Roux-Serratrice C, et al. The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). J Inherit Metab Dis. 2010;33(4):331-338.
7. Wigderson M, Firon N, Horowitz Z, et al. Characterization of mutations in Gaucher patients by cDNA cloning. Am J Hum Genet. 1989;44(3): 365-377.
8. Beutler E, Gelbart T. Gaucher disease mutations in non-Jewish patients. Br J Haematol. 1993;85(2):401-405.
9. Grabowski GA, Horowitz M. Gaucher’s disease: molecular, genetic and enzymological aspects. Baillieres Clin Haematol. 1997;10(4): 635-656.
10. Hollak CE, van Weely S, van Oers MH, et al. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 1994;93:1288-1292.
11. Barak V, Acker M, Nisman B. Cytokines in Gaucher’s disease. Eur Cytokine Netw. 1999;10:205-210.
12. Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood. 2005;105: 4569-4572.
13. Bembi B, Zanatta M, Carrozzi M, et al. Enzyme replacement treatment in type 1 and type 3 Gaucher’s disease. Lancet. 1994;344(8938): 1679-1682.
14. Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995;122(1):33-39.
15. Cox TM, Aerts JM, Andria G, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis. 2003;26(6):513-526.
16. Peterschmitt MJ, Burke A, Blankstein L, et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol. 2011; 51(5):695-705.
17. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991;324(21):1464-1470.
18. Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res. 2007;22(1):119-126.
19. Zimran A, Wang N, Ogg C, et al. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease. Am J Hematol. 2015;90(7):577-583.
20. Pastores GM, Petakov M, Giraldo P, et al. A Phase 3, multicenter, open- label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Mol Dis. 2014;53(4):253-260.
21. Sechi A, Deroma L, Dardis A, et al. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients. Mol Genet Metab. 2014;113(3):213-218.
22. Weinreb NJ, Goldblatt J, Villalobos J, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis. 2013;36(3):543-553.
23. Platt FM, Jeyakumar M. Substrate reduction therapy. Acta Paediatr Suppl. 2008;97(457):88–93.
24. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000;355(9214):1481–1485.
25. Schiffmann R, Fitzgibbon EJ, Harris C, et al. Randomized controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol. 2008;64:514–522.
26. Kuter DJ, Mehta A, Hollak CE, et al. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis. 2013;51:116–124.
27. Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J Biol Chem. 1999;274(21):14662–14669.
28. Hirth BH, Siegel C, inventors; Genzyme Corporation, assignee. Synthe­sis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors. United States patent US6855830 B2. 2002 Jul 16.
29. McEachern KA, Fung J, Komarnitsky S, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab. 2007;91(3):259–267.
30. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41:4–14.
31. Lukina E, Watman N, Arreguin EA, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116(6):893–899.
32. Lukina E, Watman N, Dragosky M, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis. 2014;53(4):274–276.
33. Kamath RS, Lukina E, Watman N, et al. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol. 2014;43(10):1353–1360.
34. Mistry PK, Lukina E, Ben Turkia H, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015;313(7):695–706.
35. Cox TM, Drelichman G, Cravo R, et al. Eliglustat compared with imiglucerase in patients with Gaucher’s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015;385(9985):2355–2362.
36. Wraith JE. Limitations of enzyme replacement therapy: current and future. J Inherit Metab Dis. 2006;29(2–3):442–447.
37. Thomas AS, Mehta A, Hughes DA. Gaucher disease: haematological presentations and complications. Br J Haematol. 2014;165(4):427–440.
38. Pavlova EV, Archer J, Wang S, et al. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J Pathol. 2015;235(1):113–124.
39. Larsen SD, Wilson MW, Abe A, et al. Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res. 2012;53(2):282–291.
40. Carreiro J, Balwani M, Grosskreutz C, et al. A case report of secondary autograft failure due to Gaucher disease. Am J Hematol. 2008;83(12):937.
41. Dahl M, Doyle A, Olsson K, et al. Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. Mol Ther. 2015;23(5):835–844.